Praxis Precision Medicines

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Praxis Precision Medicines sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials 6 currently recruiting 5 completed early-phase tilt top decile by trial count

Praxis Precision Medicines: 13 sponsored US clinical trials, 6 recruiting.

Praxis Precision Medicines sponsors 13 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 5 completed. 3 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is SCN2A Encephalopathy, with 2 trials.

Top-decile sponsor footprint

Praxis Precision Medicines ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

13 total, page 1 of 1

RECRUITING Phase 3

Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures

NCT07505004
RECRUITING Phase 3

A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety

NCT07019922
RECRUITING Phase 3

A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine

NCT07010471
RECRUITING Phase 2

An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures

NCT06908356
RECRUITING Phase 2

Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)

NCT06999902
RECRUITING Phase 1

A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy

NCT05737784
ACTIVE NOT RECRUITING Phase 2

A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)

NCT05818553
COMPLETED

A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic Encephalopathy

NCT05407727
TERMINATED Phase 2

A Clinical Trial of PRAX-114 in Participants With Post-Traumatic Stress Disorder

NCT05260541
COMPLETED Phase 2

A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor

NCT05021991
COMPLETED Phase 2

A Clinical Trial of Adjunctive and Monotherapy PRAX-114 in Participants With Major Depressive Disorder

NCT04969510
COMPLETED Phase 2

A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder

NCT04832425
COMPLETED Phase 2

A Clinical Trial of PRAX-944 in Participants With Essential Tremor

NCT05021978

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 8
Phase 3 3

Therapeutic Areas

SCN2A Encephalopathy 2
SCN8A Encephalopathy 1
Primary Generalized Epilepsy 1
Focal Onset Seizure 1
SCN2A-DEE 1
Epileptic Encephalopathy 1
Focal Seizure 1
Developmental and Epileptic Encephalopathy 1 1
Epilepsy 1

What is open in the Praxis Precision Medicines pipeline

6 recruiting of 13 indexed (46% open); 5 completed (38%).

Phase mix: 3 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: SCN2A Encephalopathy (2 trials), 8 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Praxis Precision Medicines: open-pipeline peers nationwide

Peers matched on 13 registered trials and 46% open enrollment, not the therapeutic-area sidebar.

Praxis Precision Medicines sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 020406080 0%10%20%30%40%50% Total trials Recruiting share Praxis Precision MedicinesAdaptimmuneAgennixAkili Interactive LabsAlumisNader SanaiRetina Foundation of the SouthwestSouthern College of OptometryNRG Oncology
Praxis Precision Medicines sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Praxis Precision Medicines sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 trials (± recruiting share)

Sponsors near 46% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Praxis Precision Medicines page

13 registered trials is a research-attention snapshot, not an endorsement of Praxis Precision Medicines or any single study.

  • 6 of Praxis Precision Medicines's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • SCN2A Encephalopathy is the condition Praxis Precision Medicines studies most, compare against other sponsors active in the same condition before evaluating a specific study. See SCN2A Encephalopathy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Praxis Precision Medicines pipeline card: 13 registered trials from official public datasets.Report a data error.